The sampling ofthe is not representative of use.
Inspection Record
ID Biomedical Corporation of Quebec — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The following investigation was inadequate.
The following complaint records were found incomplete and/or deficient: a.
Preventative maintenance activities were incomplete.
Procedures designed to prevent microbial contamination ofdrug products purporting to be sterile are inadequate.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- ROSLIN CELL THERAPIES LIMITED2025-01-21 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
- Sanofi Pasteur2023-09-29 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.
- Eugia Steriles Private Limited2026-06-19 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
- GSK Vaccines GmbH2024-03-06 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.